HOME >> BIOLOGY >> NEWS
Dream home: Malaria parasite renovates to suit its tastes

The malaria parasite survives in its host by remodelling the red blood cells in which it dwells. Once ensconced in its newly refurbished home, the parasite evades detection by the host's immune system. Alan F. Cowman, a Howard Hughes Medical Institute (HHMI) international research scholar at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and colleagues report on studies that reveal this clever survival strategy, in the December 10, 2004 issue of the journal Science. Their findings provide a novel target for new anti-malaria drugs.

Cowman and his research team have identified the mechanism that enables the malaria parasite Plasmodium falciparum to export proteins across a cell membrane to establish infection in the erythrocytes, or red blood cells, of the host. The researchers also have identified a subset of proteins from about 400 surveyed that appear vital to the parasite's survival in the host.

Cowman is one of 132 HHMI international research scholars in 29 countries. Through its international research program, HHMI is building a global network of outstanding scientists whose work outside the United States is contributing to our understanding of basic biological processes or disease mechanisms. There are 11 international research scholars in Australia.

P. falciparum, which infects several hundred million people each year and kills one to two million, causes the most severe form of malaria in humans. Once in the blood, the parasite's continuous asexual multiplication inside the red blood cells is responsible for the clinical symptoms of malaria and the associated incidence of disease and death.

To infect the host, the parasite exports proteins through three membranes: the parasite membrane, the parasitophorous vacuole and the erythrocyte membrane.

"It has been an enigma in biology how the parasite transfers proteins across the second membrane, the parasitophorous vacuole, and establishe
'"/>

Contact: Jennifer Donovan
donovanj@hhmi.org
301-215-8859
Howard Hughes Medical Institute
9-Dec-2004


Page: 1 2 3

Related biology news :

1. Dreaming of a nanotech Christmas: What persuades the public to embrace and buy nanotechnology?
2. Two UH grads a step closer to realizing The American Dream
3. No place like home: Ant navigation skills used in robot navigation
4. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
5. Malaria-resistant mosquitoes battle disease with molecular warhead
6. Malaria and Epstein-Barr virus linked to pediatric cancer in Africa
7. Malaria in pregnancy: What can the social sciences contribute?
8. Malaria: The right vaccine in the right place?
9. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
10. 20 Years of Malaria Research: Outcomes and Perspectives
11. Malaria poses additional risks for first-time mothers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/30/2019)... Maine (PRWEB) , ... October 29, 2019 , ... ... and calibration verification kits, for SIEMENS ATELLICA® analyzers, Order Numbers 701sa & 704sa. ... MG, NA, PHOS, UA, UTP, and UUN. , Each VALIDATE® kit, liquid, ready-to-use, ...
(Date:10/30/2019)... ... October 30, 2019 , ... Amberdata Inc., the leading blockchain ... Fenbushi Capital, DF Capital, Rising Tide Fund, and HWVP. The new investment ... accelerate its position as the leading data provider of institutional-grade blockchain and cryptoasset ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... for biopharmaceutical R&D, today announced that Octapharma, one of the world’s largest ... support the development and manufacturing of therapeutic proteins addressing severe diseases in ...
Breaking Biology News(10 mins):
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, the global leader ... announces that the U.S. Food and Drug Administration (FDA) has granted the company ... relief of chronic neck and shoulder pain of musculoskeletal origin. , Erchonia continues ...
(Date:10/3/2019)... ... October 01, 2019 , ... Today Cereset®, the ... the midway point of its randomized research trial for individuals with persisting symptoms ... the efficacy of a non-invasive technology which compares tones delivered to a subject’s ...
(Date:10/3/2019)... ... October 02, 2019 , ... Today marked ... that is enabling clinical program outsourcing success by cultivating radical improvements in leadership, ... biotech veteran executive Brenda Reese, phaseUP™ brings clients deep, broad and unique expertise ...
(Date:10/3/2019)... ... October 02, 2019 , ... eKare’s inSight® digital 3D imaging and ... run by the East Midlands Academic Health Science Network (EMAHSN), the innovation arm of ... NHS by providing support to develop and deploy solutions to the most pressing challenges ...
Breaking Biology Technology:
Cached News: